IC50 determination IC50 determination was done in either black 96-well or 384-well plates. IC50 determination for Pf20S was performed with final enzyme concentration of 2 nM activated by 12.5 nM of PA28α and 8 µM of Suc-LLVY-amc. IC50 determination for h20S was performed with final enzyme concentration of 1 nM activated by 12 nM of PA28α and 20 µM of Suc-LLVY-amc. Immunoproteasome IC50s were determined with purified rat immunoproteasome (0.25 nM) activated with 12 nM PA28a using the substrate Ac-ANW-aminocoumarin. The procedures were similar to the screening experiment except for the concentrations of compounds. IC50s were estimated by curve fitting using either Graphpad PRISM or Pipeline Pilot (Accelerys) and Genedata (Condoseo) protocols. All experiments were performed in triplicates, and values in Table  1 are the average of the triplicate.
P. falciparum replication assays P. falciparum D10 cultures were maintained, synchronized and lysed as previously described 1 . Ring stage P. falciparum culture at 2% parasitemia and 0.5 % hematocrit was added to 96-wells plates spotted with compounds. Parasites are incubated for a further 72 hr, or until schizogony was reached after one blood stage cycle and fixed in a final 1% para-formaldehyde (in PBS) for 30 min at room temperature, the nuclei stain YOYO-1 was added to a final 50 nM and incubated overnight at 4˚C. Parasite replication was monitored by observation of a YOYO-1 positive population (infected) and YOYO-1 negative population (uninfected) using a BD FACScan automated flow cytometer. All experiments were performed in triplicates, and values in Table 1 are the average of the triplicate.
For 1 hr inhibitor treatment at specific stage, synchronized parasite cultures at 2% parasitemia and 0.5 % hematocrit were treated for 1 hr with the compound, and inhibitor was removed. The culture was then washed 3 times in media and fresh media was added. The infected red blood cells were then fixed during early schizont stage in the next blood cycle, and parasitemia was analyzed using FACS as described above.
Cell viability assay in mammalian cells Human foreskin fibroblasts (HFF) were plated at 2500 cells (non-confluent) per well <24 hr before addition of the compound. Human Embryonic Kidney 293 (HEK293) cells were plated at 5000 cells per well. Compounds were diluted down for dose response concentrations in media, and added to the cells for 72 hr. Cell viability is measured using the CellTiter-Blue  Assay (Promega) as per the manufacturer's instructions. All experiments were performed in triplicates, and values in Table 1 are the average of the triplicate.
Proteasome labeling in intact P. falciparum P. falciparum at schizont stage (36-48 hr post-invasion) at 10% parasitemia and 1% hematocrit was treated with inhibitor (at 1% DMSO) for the indicated time at 37˚C. Activity-based probe MV151 2 was added directly to the culture at a final concentration of 0.5 µM and incubated for a further 30 min. The treated cultures were then transferred to Eppendorf tubes, spun down at 3200 rpm, and saponin lysed. The resulting parasite pellet was washed in phosphate-buffered saline, lysed in sample buffer, boiled and loaded onto 12% SDS-PAGE. The gel was then scanned using a flat-bed Typhoon scanner on the TAMRA channel.
Ubiquitin labeling of inhibitor treated P. falciparum P. falciparum at schizont stage was treated with inhibitor and lysate was prepared as described above. Lysates were then boiled and loaded onto 12% SDS-PAGE, transferred to nitrocellulose membrane and blotted with 1:2000 dilution of primary anti-Ubiquitin antibody (Mouse monoclonal, VU-1 from LifeSensors) followed by anti-mouse HRP secondary antibody.
Molecular docking studies
The homology models for both P. falciparum β5 and β6 20S proteasome subunits were built from the yeast proteasome structure bound to a previously published compound (PDB #3MG4) 3 using the default parameters of the molecular modeling program Molecular Operating Environment (MOE). Each side chain (from P1 to P4) was sequentially and manually changed to those of compound 1 and energy minimized individually. Each amino acid residue of the inhibitor, including the backbone and side chains, and all of the proteasome side chains within 4.5 Å were energy minimized sequentially from the P1 position to the capping group. A final energy minimization that included the entire inhibitor molecule and all the side chains within 4.5 Å was performed to generate the final models.
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Chemical Synthesis
General All solvents were purchased from Fisher Scientific (HPLC grade). All reagents were purchased from Sigma Aldrich, except mono-trityl ethylenediamine acetic acid salt and mono-trityl ethylenediamine acetic acid salt (Novabiochem), HOBt monohydrate (Advanced Chemtech) and Boc-m-(L)-tyrosine (Santa Cruz Biotechnology) and were used without further purifications. All water-sensitive reactions were preformed in anhydrous solvents under positive pressure of argon. Reactions were analyzed by LC-MS using an API 150EX single-quadrupole mass spectrometer (Applied Biosystems). Reverse-phase HPLC was conducted with an ÅKTA explorer 100 (Amersham Pharmacia Biotech) using C18 columns. NMR spectra were recorded on a Varian 400 MHz (400/100), Varian 500 MHz (500/125) or a Varian Inova 600 MHz (600/150 MHz) equipped with a pulsed field gradient accessory. Chemical shifts are given in ppm (δ) relative to tetramethylsilane as an internal standard. Coupling constants are given in Hz.
Synthesis of compound 1 4-methylbenzyl-Boc-3-Bromo-L-Phenylalanine (10). Boc-3-Bromo-L-Phenylalanine (2g, 5.81 mmol) was dissolved in dichloromethane (30 mL), and 1.1 equivalent of 4-methylbenzylamine (0.77g, 6.39 mmol), 1. 4-methylbenzyl-Boc-3-pinacolboryl-L-Phenylalanine (11). To a flask charged with 10 (720 mg, 1.61 mmol), 1.1 equivalent Bis(pinacolato)diboron (448 mg, 1.77 mmol), 3 equivalent potassium acetate (481 mg, 4.83 mmol) and [1,1'-Bis(diphenylphosphino) ferrocene]dichloropalldium (II) (40.3 mg, 0.0483 mmol) was added dry and degassed 1,4-dioxane. Reaction was stirred at 80˚C for 24 hr, after which more reagents were added (at half the amount as above) to promote the reaction. The reaction was stirred for a further 3 hr at 80˚C and the crude mixture is cooled, filtered over a celite column and concentrated in vacuo. Product was purified on flash column chromatography (10% EtOAc/hexane -> 50% EtOAc/hexane) to yield a colorless oil (530 mg, 67%). Intermediate 12. Pinacol protected boronate 11 (160 mg, 0.324 mmol) was stirred for 1 hr in 4M HCl in 1,-4 dioxane, concentrated in vacuo and co-evaporated with toluene to yield the deproptected amine. This was then added to a flask with Boc-hPhe-OH (99.4 mg, 0.356 mmol), EDC/HCl (68.2 mg, 0.356 mmol), HOBT (48.1 mg, 0.356 mmol) which were pre-dissolved in dry DCM. Reaction was left at room temperature for 6 hr, quenched with 1M HCl, and extracted 3 times with DCM. The extract was washed in saturated sodium bicarbonate, brine, dried over MgSO 4 and concentrated vacuo. Flash column chromatography (10% EtOAc/hexane -> 45% EtOAc/hexane) yielded compound 3 ( 160 mg, 75% yield) as a white crystal. 1 H NMR (400 MHz, CDCl 3 ) δ 7.66 (d, J = 6.6 Hz, 1H), 7.63 (s, 1H), 7.37 -7.22 (m, 4H), 7.21 -7.14 (m, 1H), 7.14 -7.08 (m, 2H), 7. Intermediate 14. Intermediate 13 (75 mg, 0.0963 mmol) was dissolved in acetone (6ml), and 3 equiv of sodium periodate and ammonium acetate in water (5 mL) was added Reaction was stirred at room temperature for 18 hr, and then concentrated in vacuo. The resulting residue was dissolved in NaOH, and washed in DCM. The solution was then carefully acidified to pH 2 with 1M HCl, extracted 4 times with DCM and concentrated in vacuo. The resulting product was immediately dissolved in anhydrous DCM, and 2 equiv copper (II) acetate (36 mg, 0.2 mmol), 10 equiv methanol (40 µL., 0.98 mmol), 10 equiv triethylamine (136 µL, 0.98 mmol) and 4Å molecular sieves added. Reaction was stirred at room temperature for 4 hr, passed through a celite column, concentrated in vacuo and dissolved in DMSO. The product was purified by HPLC (preparatory reverse phase C18 column, CH 3 
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